A new study from Harvard MedSchool found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss were at higher risk of having a potentially blinding eye condition called Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), than patients not taking these drugs. The study found that people with diabetes who had been prescribed semaglutide were more than 4 times more likely to be diagnosed with NAION, and those with overweight or obesity more than 7 times.